Success Metrics

Clinical Success Rate
81.8%

Based on 9 completed trials

Completion Rate
82%(9/11)
Active Trials
0(0%)
Results Posted
44%(4 trials)
Terminated
2(14%)

Phase Distribution

Ph phase_4
6
43%
Ph phase_1
1
7%
Ph phase_2
2
14%
Ph phase_3
3
21%

Phase Distribution

1

Early Stage

2

Mid Stage

9

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 2Efficacy & side effects
2(16.7%)
Phase 3Large-scale testing
3(25.0%)
Phase 4Post-market surveillance
6(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

9 of 12 finished

Non-Completion Rate

25.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(9)
Terminated(3)
Other(2)

Detailed Status

Completed9
unknown2
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
81.8%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (8.3%)
Phase 22 (16.7%)
Phase 33 (25.0%)
Phase 46 (50.0%)

Trials by Status

unknown214%
withdrawn17%
terminated214%
completed964%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT04606264Phase 3

Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data

Completed
NCT02431702Phase 3

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

Completed
NCT02893371

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
NCT05762146Phase 2

Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE

Unknown
NCT02199743Phase 4

Lurasidone Effects on Tissue Glutamate in Schizophrenia

Completed
NCT02600741

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Completed
NCT02307396Phase 4

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

Completed
NCT02374567Phase 3

Pharmacovigilance in Gerontopsychiatric Patients

Terminated
NCT00014001Phase 4

CATIE- Schizophrenia Trial

Completed
NCT01157351Phase 4

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

Completed
NCT01193166Phase 4

Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital

Withdrawn
NCT00802100Phase 4

Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia

Completed
NCT00737256Phase 2

A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence

Unknown
NCT00480246Phase 1

A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14